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  37 
Abstract 38 
 39 
Currently, it is unclear to what extent sampling procedures affect the epigenome. Here, this 40 
phenomenon was evaluated by studying the impact of artery ligation on DNA methylation in 41 
clear cell renal cell cancer. To this end, DNA methylation profiles between vascularised tumour 42 
biopsy samples and devascularized nephrectomy samples from two individuals were 43 
compared. The relevance of significantly altered methylation profiles was validated in an 44 
independent clinical trial cohort. We found that six genes were differentially methylated in 45 
the test samples, of which four were linked to ischaemia or hypoxia (REXO1L1, TLR4, hsa-mir-46 
1299, ANKRD2). Three of these genes were also found to be significantly differentially 47 
methylated in the validation cohort, indicating that the observed effects are genuine. Based 48 
on these results, we conclude that the impact of sampling procedures in clinical epigenetic 49 
studies should be considered, particularly after inducing hypoxia/ischemia, which occurs in 50 
many oncological surgery procedures through which tissues are harvested for translational 51 
research. 52 
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1 Introduction 58 
 59 
The use of clinical samples in epigenetics research has become routine [1–3]. However, the 60 
nature of the sampling procedures may significantly compromise the resulting epigenetic 61 
profiles, leading to an “epigenetic observer effect". In renal cell carcinoma (RCC), dynamic 62 
molecular changes occur over time and with therapy, which require serial tissue samples for 63 
elucidation [4,5]. Despite the development of standard operating procedures for tissue 64 
acquisition and biobanking, less attention is paid to ensuring constant, robust pre-collection 65 
conditions, such as warm ischaemia time, than to post-collection handling and processing 66 
procedures, thus failing to avoid variation due to pre-analytical factors [6]. There are 67 
recommended tissue sampling guidelines from organisations such as the Confederation of 68 
Cancer Biobanks, which advise that warm ischaemia time should be minimised as much as 69 
possible prior to freezing of fresh tissue samples, but this is very difficult to measure and 70 
standardise [7]. Several studies have looked at the procurement conditions on RNA biomarker 71 
expression and the effect on previously identified cancer biomarkers [8], but so far there have 72 
been no such studies on DNA methylation. 73 
Prolonged ischaemia leads to higher levels of tissue hypoxia, which has been shown to 74 
induce DNA demethylation in e.g. hepatoma cells [9]. This demethylation has been shown to 75 
be induced by methionine adenosyltransferase 2A (MAT2A), of which the expression is 76 
positively regulated by HIF-1a [9], which in turn is negatively regulated by VHL [10]. VHL plays 77 
a crucial role in RCC development [11]. Hypoxia, methylation and RCC form, therefore, an 78 
intricate network of which the components cannot be studied separately. Yet, different RCC 79 
sampling procedures might obfuscate the results by influencing the hypoxic conditions. More 80 
than most tumours, RCC sampling is challenging as the majority of the extirpative procedures 81 
deal with minimally invasive approaches. It is well established that changes occur in mRNA 82 
levels with increasing time after renal artery clamping in RCC [12]. Here, we assessed the effect 83 
of renal artery clamping on the RCC methylome. 84 
 85 
Patient samples and methods 86 
 87 
Patient-matched sample sets were obtained from two patients who, at the time of open 88 
cytoreductive nephrectomy for metastatic clear cell RCC (ccRCC), had fresh ccRCC tumour 89 
biopsies taken prior to ligation of the renal artery after which matched fresh frozen tumour 90 
samples were harvested following ligation and division of the renal artery and removal of the 91 
kidney as per a previously described approach [5]. A total of 12 samples was collected, i.e., 3 92 
biopsy and 3 nephrectomy samples from each patient. These samples were obtained as part 93 
of the Scottish Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC) 94 
study (East of Scotland Research Ethics Service REC 1: 10/S1402/33). For validation purposes, 95 
but also to evaluate the potential impact on clinical epigenetics research, matched tumour 96 
samples taken at the time of diagnostic renal tumour biopsy and subsequent nephrectomy 97 
were obtained from 14 patients with metastatic ccRCC. Following primary tumour biopsy, 98 
these patients were treated with three cycles of sunitinib (18 weeks) followed by 99 
cytoreductive nephrectomy after 2 weeks of sunitinib as part of the Upfront Sunitinib 100 
(SU011248) Therapy Followed by Surgery in Patients with Metastatic Renal Cancer: a Pilot 101 
Phase II Study (SuMR; ClinicalTrials.gov identifier: NCT01024205) [13]. All samples used in this 102 
study are listed in Supplementary file 1. 103 
Extraction of genomic DNA was performed using a Qiagen DNeasy Blood and Tissue 104 
(Qiagen, UK) kit following the manufacturer's instructions. DNA methylation analyses using 105 
MBD sequencing was carried out as described previously [14]. A MethylCap kit (Diagenode, 106 
Belgium) was used for capturing methylated fragments from 500 ng starting material. 107 
Massively parallel sequencing of these fragments was subsequently performed on an Illumina 108 
HiSeq 2000 machine (Illumina, San Diego, CA, USA). 109 
Raw data files were mapped using BOWTIE to the human reference genome 110 
Hg19/GRCh37, and summarized using an in-house developed Map of the Human Methylome 111 
[15] consisting of a putative genome-wide overview of potentially methylated loci 112 
(“methylation cores”). Further data analyses were performed using Python 3.4.3 and R 3.2.1. 113 
The Bioconductor quantro software package (1.2) was used to assess quantile normalization 114 
assumptions [16], whereas the limma software package (3.24.15) was used to identify regions 115 
featured by differential methylation patterns. Prior to limma analysis, the samples were 116 
quantile normalized and transformed using the voom function [17]. Only methylation cores 117 
that referred to annotated promoter regions (including exon1), and that had at least an 118 
average coverage of one mapped fragment per sample, were withheld for analysis. Low 119 
coverage loci are featured by a too low power to be detected as differentially methylated, 120 
thereby unnecessarily inflating the amount of hypotheses tested, which justifies their 121 
unsupervised removal from the dataset. Regions with a False Discovery Rate (FDR) < 0.05 were 122 
selected for further assessment using the sample dataset [13]. For the validation dataset, the 123 
FDR estimation (Benjamini-Hochberg) was based on the amount of loci to be validated. 124 
 125 
Results and discussion 126 
 127 
A quantro test was performed to check the suitability of the samples for quantile 128 
normalization, which was used for limma-voom. A p-value of 0.53 was obtained after 1000 129 
permutations, implying that there were no global differences in the distributions between the 130 
non-ischaemic biopsy and ischaemic nephrectomy samples. A limma-voom data analysis was 131 
subsequently performed using quantile normalization. In Table 1 seven regions are listed that 132 
were found to be differentially methylated up to an FDR of 0.05 (Fig 1 ). Only two of these 133 
seven (AC232323.1 and ANKRD2) exhibited a relative hypomethylation in the ischaemic 134 
nephrectomy samples compared to the non-ischaemic samples. In one of these (AC232323.1) 135 
a different region (8325757) exhibited a significant relative hypermethylation. 136 
The differentially methylated regions with a FDR < 0.05 were subsequently subjected 137 
to validation using methylation data obtained from matched biopsy and nephrectomy 138 
samples from the SuMR clinical trial. Three of the seven regions identified in the test set, were 139 
again significantly altered at the same level within the validation cohort (AC232323.1 region 140 
8325757, REXO1L1 and OR6Q1). A binomial test – using the FDR threshold as expected 141 
probability – rejected the null hypothesis that this would have occurred randomly (p = 0.004). 142 
We therefore hypothesise that the shared results between the two studies are caused by 143 
ischaemic conditions. Of the 7 loci identified in the test set, 6 were found to have the same 144 
fold change direction in the validation cohort. However, assuming a 50% random chance of 145 
having the same fold change direction, the number of similar direction of change was not 146 
found to be significant (p = 0.125). A lower FDR cut-off of 10% yielded 36 significant regions, 147 
yet this cut-off was deemed not sufficiently conservative as the fraction that could be 148 
validated in the validation cohort was too low to reject the null hypothesis of significant 149 
overlap (p = 0.085, data not shown). 150 
Methylation meta-analyses have shown that DNA methylation is a critical event in 151 
tumorigenesis [18]. It is, therefore, surprising that an analysis of the effect of tissue 152 
procurement on DNA methylation has so far not been performed, as it has in other molecular 153 
analyses. From our test and validation results it is clear that ischaemic conditions, induced as 154 
part of the surgical procedure, may lead to differential methylation. 155 
The results of the study presented here indicate that the RCC methylome may be 156 
modulated following renal artery ligation. Global gene demethylation in samples was not 157 
observed, but consistent demethylation of at least one individual gene (ANKRD2) was found. 158 
These results hold considerable significance for translational methylation research for solid 159 
tumours obtained by extirpative surgery, especially where minimally invasive surgical 160 
approaches are used. The most significantly affected gene, AC232323.1, encodes a long non-161 
coding RNA (lncRNA) product. According to LNCipedia [19] this lncRNA is linked to the second 162 
most significantly affected gene, REXO1L1, and has potential direct biological relevance 163 
(http://www.lncipedia.org/db/transcript/lnc-REXO1L2P-1:1). REXO1L1 was found to be 164 
hypermethylated following renal artery clamping. REXO1L1 deletions have been linked to 165 
increased apoptosis under certain conditions [20], such as intense hypoxia, which may 166 
underlie the results presented above [21]. The third significantly affected gene, TLR4, plays a 167 
crucial role in kidney ischemia/reperfusion injury [22], and Hsa-mir-1299 also has a possible 168 
role in apoptosis through interaction with PIM1 [23]. The OR6Q1 gene encodes an olfactory 169 
receptor and is, therefore, an unlikely candidate, although it should be noted that there is 170 
evidence for a limited expression in other tissues as well [24]. Finally, ANKRD2 belongs to the 171 
conserved muscle ankyrin repeat protein (MARP) family. Expression of MARPs has been found 172 
to be induced in response to physiologic stress, injury, hypoxia and hypertrophy [25,26] and 173 
the ANKRD2 mRNA level has indeed been found to be upregulated under specific hypoxic 174 
conditions. Our results indicate that this upregulation may be brought about by demethylation 175 
of a specific methylation core. 176 
Despite the test and validation cohorts used, this study should be considered as proof 177 
of principle with a necessarily low power, as it was deemed unethical to expose subjects to an 178 
extra pre-operative percutaneous biopsy procedure without clinical benefit. Also, in the 179 
validation cohort, patients were treated with sunitinib, the time between biopsy and 180 
nephrectomy was longer (20 weeks) and the sequencing depths were generally more shallow, 181 
implying that additional discrepancies between both datasets may have been caused by 182 
treatment, temporal or other technical reasons. 183 
Taken together, our data indicate that in both a test and a validation cohort renal 184 
artery ligation modulates gene methylation in a biologically relevant fashion. As with any 185 
research using surgically resected clinical samples, future methylation studies must be 186 
designed to include robust and well-documented sample procurement techniques in order to 187 
take these findings into account. 188 
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Legend tot the Figure 212 
 213 
Figure 1 Sampling procedure differences. For each of the regions with a FDR < 0.05, boxplots 214 
of the methylation counts are shown. The methylation core region is shown under the gene 215 
label. 216 
 217 
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